Kornimate/medical-research-clean huggingface dataset:
emotional information processing in attention deficit disorder with or without hyperactivity

Conditions: Attention Deficit Disorder With Hyperactivity; Attention Deficit Disorder Without Hyperactivity

Summary: the aim of this study is to analyse explicit and implicit emotional information processing abilities in children with attention deficit disorder with or without hyperactivity

the main symptoms of attentional deficit hyperactivity disorder (adhd) are inattention, motor agitation and impulsivity. however, other dysfunctions affecting the quality of life remain poorly studied: lack of understanding and management of emotions, focus on the local aspects of a visual scene limiting the ability to assign a general meaning to the scene and alteration of long-term memory encoding. this study aims to analyse these difficulties using different tasks requiring processing of rich and varied everyday images, having high ecological validity. it involves the participation of 56 boys and girls with adhd, aged 7 to 12 years. a first phase examines the immediate understanding of images using two tasks: semantic categorization (experiment 1) and emotional evaluation (experiment 2) of images with positive, negative or neutral emotional valence, and depicting real environments (natural vs. manufactured contexts) or foreground objects pasted into a noise background (inanimate objects vs. animals vs. people. in each trial, one context image and one object image are presented briefly and simultaneously, one in each visual field. in order to be appropriately understood in both their semantic and emotional contents, context images will require more global processing, while object images will require more local, detailed processing. their semantic (exp. 1) and emotional (exp. 2) consistency is manipulated. a week later, the participants have to perform a memory task requiring old/new recognition in a two-alternative forced choice (2afc) paradigm that presents in each trial a pair of images (one old, one new) having the same emotional valence (exp. 3). the study will characterize the specificities of processing and representing visual emotional information in adhd children. the results will be compared with those from a previous study we conducted with the same methodology on neuro-typical children (controls).

Eligibility criteria:
inclusion criteria: * children between 7 and 12 years old.................................. * normal or corrected visual acuity ..................................... * adhd diagnostic given by a doctor according to dsm 5 criteria (diagnostic and statistical manual of mental disorders) * free from drug treatment until 24 hours before the experiment session............................ * affiliation to a social security system......................... * signature of the authorization documents from one parent or the holder of parental authority exclusion criteria: -history of neurological troubles, dysphasia, autistic spectrum disorder, intellectual disabilities
can diffusion tensor imaging (dti) of the optic ways contributes to predict the 6 months prognosis of optic neuritis (on)?

Conditions: Optic Neuritis

Summary: can diffusion tensor imaging (dti) of the optic ways contributes to predict the 6 months prognosis of optic neuritis (on)?


Eligibility criteria:
inclusion criteria: * age from 18 to 55 years old * clinically suspected optic neuritis defined as a sudden decrease of the visual acuity and/or a damage to the field of vision and/or a defect of the colour vision and/or retro-orbital pain with a relative afferent pupillary defect (except if the optic neuropathy is bilateral or symmetrical), in the absence of a severe retinal macular pathology, and in the absence of a toxic or iatrogenic intake (ethambutol, vfend) * clinical optic neuritis duration \< 15 days * first episode of an inflammatory on * no corticosteroids in the month before * indication to a corticosteroid therapy at high dose to cure the felt symptomatology * retinal nerve fibre layer (rnfl) thickness upper 75 µm at initial stage * isolated on, multiple sclerosis or nmo (neuro myelitis optica) - sd (spectrum disorder) context * having signed informed consent for participating in the study exclusion criteria: * contra-indication to mri * cardiac pacemaker or defibrillator implant * neurosurgical clips * cochlear implants * intra-orbital or encephalic foreign bodies * stents implanted since less than 4 weeks and osteosynthesis equipment implanted since less than 6 weeks * claustrophobia * persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty * eye examination suggests a pre-existing eye abnormality that could affect the visual function (amblyopia, strong myopia...) * pregnant or breastfeeding women
the impact of indocyanine green-enhanced fluorescence imaging on bowel transection in left-sided colorectal resection

Conditions: Anastomotic Leak

Summary: the aim of this study was to evaluate the impact of fluorescence imaging on the location of colorectal transection lines based on evaluation of perfusion with indocyanine green, how it's going to affect surgical planning and its possible benefits in reducing anastomotic leakage.

during surgery, the line of intended bowel transection would be determined by the surgeon. then the anesthesiologist will administer a bolus of 5mg icg intravenously (2.5mg/ml, 2ml), followed by 10ml normal saline flush. the perfusion of colon will be assessed via fluorescence angiography. the actual bowel transection, after icg fluorescence study, would be compared with the intended bowel transection site. the difference in terms of distance and either more proximal or distal is recorded. then bowel anastomosis is completed in the usual manner.

Eligibility criteria:
inclusion criteria: * all left-sided colorectal resection involving division of inferior mesenteric artery exclusion criteria: * patients with a history of adverse reaction or known allergy to icg, iodine, or iodine dyes. pregnant and/or lactating patients.

Keywords: icg colectomy anastomotic leak anastomotic leakage rate surgical decision
phase ii study of spi-1620 in combination with docetaxel as a second-line to treat biliary cancer

Conditions: Biliary Cancer

Summary: the primary purpose of this study is to determine the effectiveness of spi-1620 in combination with docetaxel in patients with advanced biliary cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed biliary tract or gallbladder cancer that have relapsed or are refractory after one prior gemcitabine-based chemotherapy regimen for advanced biliary cancer * evaluable disease * ecog ps ≤ 2 * adequate bone marrow, liver and renal function exclusion criteria: * treatment with more than one prior chemotherapy regimen * known, uncontrolled cns metastases * baseline peripheral neuropathy ≥ grade 2. * significant circulatory disorders in the past 6 months * concomitant use of phosphodiesterase inhibitors
s protein and covid-19: a monocentric prospective study

Conditions: COVID-19

Summary: the aim of this study is to compare plasma s protein levels to sars-cov-2 viral load in covid positive patients.

non-pharmacological, non-interventional, prospective, monocentric study involving the use of biological materials. there will be two cohorts: * covid + cohort: 50 patients with positive nasopharyngeal swab and / or bal. * control cohort: 20 patients with non-sars-cov-2 related pneumonia. the study involves analyzing biological samples collected for normal clinical practice. in particular: * blood samples will be used for pros and sflt1 assay, haematological, biochemical and coagulation tests. * samples deriving from nasopharyngeal swab or from broncho-alveolar lavage (bal) liquid will be used for real time pcr analysis to evaluate the viral load of sars cov-2.

Eligibility criteria:
inclusion criteria: cohort covid + : * subjects aged ≥ 18 years. * signing of the informed consent. * positivity for sars-cov-2 by realtimepcr from nasopharyngeal swab or bronchial wash. cohort control: 1. subjects aged ≥ 18 years. 2. signing of the informed consent. 3. diagnosis of pneumonia not related to sars-cov-2, demonstrated by negative swab. exclusion criteria: * patients with a diagnosis of congenital s protein deficiency. * patients who are taking oral anticoagulant therapy (tao) or new oral anticoagulants (nao). * chronic liver failure (\> 5 points on the child-pugh score). * female subjects who are pregnant or on estrogen-progestogen replacement therapy.

Keywords: pros s protein sars-cov-2 covid-19
a study of ro4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia (wn25306)

Conditions: Schizophrenia

Summary: this randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of ro4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia. patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of ro4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * diagnosis of schizophrenia * clinical stability for 16 weeks (4 months) prior to randomization * antipsychotic treatment stability for the past 12 weeks prior to randomization * with the exception of clozapine, patients are on any of the available marketed atypical or typical antipsychotic (treatment with a maximum of two antipsychotics) exclusion criteria: * has treatment resistant schizophrenia as judged by the treating physician or have failed two trials * evidence that patient has clinically significant uncontrolled or unstable medical disorder (e.g. cardiovascular, renal hepatic, gastrointestinal, hematologic, immunological, neurological, endocrine, metabolic or pulmonary disease) * patient has a body mass index (bmi) of \ 40 kg/m2, respectively) * diagnosis of mental retardation or severe organic brain syndromes * in the investigator's judgment, a significant risk of suicide or violent behavior
observe change in nasal swab drd2 gene expression in restless legs syndrome (rls) patients on prolonged dopamine agonist treatment

Conditions: Restless Leg Syndrome (RLS)

Summary: the study aims to observe changes in dopaminergic genes expression in peripheral tissue upon prolonged dopamine agonist treatment on patients with restless legs syndrome (rls). similar studies in parkinson's disease have shown changes in alpha-synuclein expression, which might offer insights into the dopaminergic gene regulation seen in rls. the dopamine agonist drugs to be included in this study are: pramipexole (mirapex), ropinirole (requip), rotigotine (neupro), apomorphine (apokyn), bromocriptine (parlodel). specifically, the study will collect nasal swabs of participants partitioned into two groups, those who have not used a dopamine agonist or been on a dopamine agonist for less than 1 month compared to those who have been on the medication for 6 or more months. this research could provide insight into changes in dopaminergic gene expression associated with augmentation syndrome (as) which occurs after long term dopamine agonist treatment in rls patients.


Eligibility criteria:
inclusion criteria: * able to provide informed consent * clinical diagnosis of restless legs syndrome (rls) * on-going treatment with a dopamine agonist exclusion criteria: \* use of any medication that might affect nasal epithelial cell collection with a nasal swab

Keywords: restless leg syndrome rls neurological
a study to evaluate the mechanism of action of ruxolitinib cream in subjects with vitiligo (true-v moa)

Conditions: Vitiligo

Summary: the purpose of the study is to evaluate the mechanism of action (moa) of ruxolitinib cream in vitiligo by assessing the change in biomarkers.


Eligibility criteria:
inclusion criteria * a clinical diagnosis of nonsegmental vitiligo with depigmented areas including ≥ 0.5% bsa on the face, ≥ 0.5 f-vasi, ≥ 3% bsa on nonfacial areas, and ≥ 3 t-vasi; total body vitiligo area (facial and nonfacial) should not exceed 50% bsa. * at least 1 active vitiligo lesion (eg, such as confetti lesion, trichrome appearance, pinkish rim, or other evidence of inflammatory activity) at the site for skin biopsy. * agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted. exclusion criteria * no pigmented hair within any of the vitiligo areas on the face. * other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor). * used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas except hydroquinone. * any other skin disease that, in the opinion of the investigator, would interfere with the study medication application or study assessments. * conditions at baseline that would interfere with evaluation of vitiligo. * use of any protocol-defined treatments within the indicated washout period before baseline.

Keywords: vitiligo depigmenting disorder topical jak inhibitor
effect of high-dose guarana and cancer-related fatigue

Conditions: Cancer-related Fatigue

Summary: this research will examine the effectiveness of a guaraná nutrition energy bar supplement on cancer-related fatigue based on scores from fatigue questionnaires. participants will be randomized to one of three study arms: 1) two guaraná energy bars/day, 2) one guaraná energy bar/day 3) usual-care only/ no guaraná energy bars during study in cancer patients who have completed cancer treatment. we would also like to find out if this energy bar supplement improves physical performance, mood and reduces plasma glutamine and inflammation.


Eligibility criteria:
inclusion criteria: * have a confirmed diagnosis of a malignant solid tumor between 4 and 36 months post-treatment (pathology report or md documentation). * completed all forms of standard treatment (surgery, chemotherapy, radiation therapy, and/or immunotherapy) between 4 and 36 months prior to enrollment in the study. * be 18 years of age or older. * have cancer-related fatigue, as indicated by a response of a 4 or greater when asked to rate their level of fatigue at its worst in the past week on an 11-point scale anchored by "0": = 'no fatigue' and "10" = 'as bad as you can imagine' as taken from a single item question on the symptom inventory questionnaire. * be able to read english (since the assessment materials are in printed format). exclusion criteria: * participants must not: have used guaraná supplements within the previous two months. * self-report that they are very sensitive to caffeine. * uncontrolled hypertension * have an allergy to walnuts, seaweed, soybeans and/or chocolate. * use medications for which caffeine intake is contraindicated including: β-adrenergic agonists, and/or medications that contain pseudoephedrine.
application of cultured autologous keratinocytes for burn wound healing

Conditions: Burns

Summary: in this study the treatment of full thickness burn wounds with cultured autologous keratinocytes in combination with meshed split skin autograft versus meshed split skin graft alone will be compared. it is expected that the application of cultured autologous keratinocytes in combination with a meshed split skin autograft will improve wound healing and scar formation.

the standard treatment for extensive burn wounds is transplantation with meshed split skin graft. disadvantages of this treatment are that healing of large full thickness burn wounds is still accompanied by scar formation. even standard treatment, transplantation with a (meshed) split skin autograft, does not result in satisfactory functional and cosmetic appearance of the healed wound. due to limited available donor sites meshes needs to be enlarged. bigger enlargements of meshes give more scarring and mesh pattern are still visible in scars, probably because wound closure still needs several weeks. application of cultured autologous keratinocytes may enhance wound closure and improve outcome of healing. primary objective: does the application of cultured autologous keratinocytes on deep burn wounds accelerate wound closure secondary objectives: does the application of cultured autologous keratinocytes on deep burn wounds improve scar quality with respect to scar elasticity, colour/pigmentation and/or smoothness after 3 and 12 months.

Eligibility criteria:
inclusion criteria: * competent and temporarily incompetent patients 18 years of age or older with acute burn wounds that require widely meshed skin grafting, which do not need immediate excision * minimal study wound area 100 cm2 * maximal study wound area 300 cm2 * maximal tbsa 30% full thickness wounds * informed consent exclusion criteria: * immunocompromised patients * infected wounds * use of high doses of (.20mg/pd) corticosteroids and/or cytostatica * known penicillin allergy * conditions where the patient is non compliant as judged by a medical specialist

Keywords: burns cultured autologous keratinocytes wound healing wound closure scar quality
comparison of two temperatures to treat insomnia

Conditions: Primary Insomnia

Summary: insomnia patients demonstrate subjective and physiological hyperarousal. the cereve sleep system has been proposed as a clinical treatment to reverse this hyperarousal in insomnia patients. the current study is a two dose study to determine the optimal temperature for the cereve sleep system. primary outcome measures include eeg sleep measured sleep latency and sleep efficiency.


Eligibility criteria:
inclusion criteria: age \>/= 22 diagnosis of insomnia that meets criteria for dsm iv diagnosis of primary insomnia and international classification of sleep disorders (icsd)general insomnia criteria and rdc insomnia disorder criteria subjects must remain alcohol-free and avoid drugs that could affect sleep during the study. \>14 on the insomnia severity index sleep -wake diaries demonstrate sleep efficiency \<85% on at least 50% of nights exclusion criteria: neuropsychiatric disorders that may independently affect sleep, brain function or cognition, such as current major syndromal psychiatric disorders, including dsm-iv mood, anxiety, psychotic, and substance use disorders. specific exclusionary diagnoses include major depressive disorder, dysthymic disorder, bipolar disorder, panic disorder, obsessive compulsive disorder, generalized anxiety disorder, any psychotic disorder, and any current substance use disorder. unstable medical conditions raynaud's disease irregular sleep schedules including shift workers; a latency to persistent sleep \< 15 on either the sleep disorder screening night or the baseline psg sleep night; a sleep efficiency \> 85% on either the sleep disorder screening night or the baseline psg sleep night; an ahi (apnea hypopnea index) \> 10 and/or a periodic limb movement arousal index (plmai) \> 15 from sn1 body mass index \>34 use of medications known to affect sleep or wake function consumption of more than one alcoholic drink per day, or more than 7 drinks per week prior to study entry. caffeinated beverages \> 4/day or the equivalent of more than 4 cups of coffee unable to read or understand english
exploratory safety study of ald518 in subjects with steroid-refractory acute graft versus host disease (gvhd)

Conditions: Acute GvHD

Summary: the purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ald518 in subjects with acute gvhd, who have failed to respond to glucocorticosteroids, for further investigation in part b.


Eligibility criteria:
inclusion criteria: * glucocorticosteroid refractory acute gvhd grade 2-4 * prior corticosteroid therapy at \> 1.0mg/kg methylprednisolone or equivalent for minimum of 3 and maximum of 14 days * karnofsky performance satus scale ≥ 50% * adequate laboratory testing at screening exclusion criteria: * subjects having stage 1 skin acute gvhd * subjects with stage 3 or 4 liver gvhd * prior ebv associated malignancy * prior or current hepatitis b or c * prior or active tuberculosis

Keywords: allograph steroid refractory
shockwave therapy versus lipus on mandibular fracture bone healing

Conditions: Mandibular Fractures

Summary: compare between the effect of shockwave therapy and low-intensity pulsed ultrasound on healing process of fresh mandibular fractures

the mandible is the commonest facial bone to fracture. mandibular fractures represent more than 74% of all maxillofacial fractures. to compare between the effect of shockwave therapy and low-intensity pulsed ultrasound on healing process of fresh mandibular fractures. a total of 21 patients; aged between 20-40 years, who have mandibular fracture were selected for this study from the outpatient clinic of the oral and maxillofacial surgery department, faculty of dentistry, alexandria university. in this study all patients were subjected to closed reduction and intermaxillary fixation. this will be followed by shockwave therapy in seven patients as a study group and by low-intensity pulsed ultrasound in seven patients as study group. seven patients will receive neither and will constitute the control group.

Eligibility criteria:
inclusion criteria -patients selected for this study will have fresh fracture mandible which is indicated for closed reduction. exclusion criteria -patients having the following criteria will be excluded scars, burns, infection in the skin in the relevant working area
salud diabetes: a pilot study comparing lifestyle interventions and real-time continuous glucose monitoring

Conditions: Diabetes; Nutrition

Summary: the aim of this proposal is to determine the impact of a produce prescription program in predominantly hispanic/latino adults with established non-insulin treated t2d and an hba1c at or above 9%.

the aim of this proposal is to determine the impact of a produce prescription program in predominantly hispanic/latino adults with established non-insulin treated t2d and an hba1c at or above 9%. for individuals not responding to the produce prescription program, they will be randomized to the addition of real-time continuous glucose monitoring (rtcgm) or continue with the produce prescription program only for a further 3 months.

Eligibility criteria:
inclusion criteria: adults (aged\>18 years) with established t2d and hba1c of 9% or higher per most recent test result within the last 6 months. agreement to only track glucose levels via study-provided cgm - exclusion criteria: type 1 diabetes, insulin use, pregnancy, use of steroids or medications that impact glucose levels medications include: atypical antipsychotics clozapine olanzapine paliperidone quietiapine risperidone corticosteroids calcineurin inhibitors cyclosporine sirolimus tacrolimus protease inhibitors atazanavir darunavir fosamprenavir indinavir nelfinavir ritonivir saquinavir tipranivir life expectancy less than 6 months diagnosis of stage 5 kidney disease or at risk of needing dialysis per investigator discretion any active clinically significant disease or disorder which in the investigator's opinion could interfere with participation in the study. inability to follow study procedures per investigator discretion -

Keywords: type 2 diabetes diabetes nutrition vegetables fruits